Angela Applebee, MD
Neurology · Albany, NYNPI 1508051517
Payments from drug & device makers
Across 858 payments — averaging $668.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$189K
- EMD Serono, Inc.$132K
- Sanofi$90K
- Genentech USA, Inc.$89K
- F. Hoffmann-la Roche AG$37K
- Novartis$13K
- plus $25K from 27 others
What the payments were for
- Consulting fees$101,58519%
- Speaking & faculty fees$399,74274%
- Travel & lodging$17,3783%
- Food & beverage$17,8103%
- Education$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 167 | $188,615 |
| EMD Serono, Inc. | 129 | $131,533 |
| Sanofi | 94 | $90,027 |
| Genentech USA, Inc. | 77 | $88,651 |
| F. Hoffmann-la Roche AG | 1 | $37,091 |
| Novartis | 77 | $12,890 |
| Bristol Myers Squibb | 44 | $9,173 |
| E.r. Squibb & Sons, L.L.C. | 8 | $6,210 |
| AbbVie(2 entities) | 198 | $3,955 |
| Amgen(2 entities) | 9 | $1,897 |
| AstraZeneca | 6 | $1,880 |
| TG Therapeutics, Inc. | 2 | $874 |
| Supernus Pharmaceuticals, Inc. | 15 | $237 |
| Johnson & Johnson | 5 | $199 |
| Lundbeck LLC | 2 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Lilly USA, LLC | 2 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Harmony Biosciences LLC | 1 | $37 |
| Scilex Pharmaceuticals Inc. | 2 | $34 |
| Pfizer | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $23 |
| Livanova USA, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| SK Life Science, Inc. | 1 | $20 |
| Banner Life Sciences, LLC | 1 | $19 |
| Impel Pharmaceuticals LLC | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Genentech, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$573,784 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 60 | $603,169 |
| Teriflunomide | 160 | $473,080 |
| CopaxoneGlatiramer Acetate | 62 | $425,575 |
| Dalfampridine ErDalfampridine | 434 | $421,545 |
| TecfideraDimethyl Fumarate | 38 | $324,322 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 20 | $273,984 |
| BetaseronInterferon Beta-1b | 28 | $264,140 |
| AmpyraDalfampridine | 38 | $239,011 |
| GilenyaFingolimod Hcl | 18 | $188,205 |
| Kesimpta PenOfatumumab | 19 | $154,128 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 13 | $127,958 |
| Nurtec OdtRimegepant Sulfate | 68 | $102,817 |
| Glatiramer Acetate | 53 | $100,378 |
| ZeposiaOzanimod Hydrochloride | 12 | $97,426 |
| GlatopaGlatiramer Acetate | 28 | $91,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $90,027 | $603,16960 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $15 | $425,57562 claims |
| BiogenTecfidera | $188,615 | $324,32238 claims |
| NovartisGilenya | $12,890 | $188,20518 claims |
| AbbVieQulipta, Ubrelvy | $3,955 | $105,15290 claims |
| PfizerNurtec Odt | $33 | $102,81768 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $6,210 | $97,42612 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $38 | $28,86718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.
Other neurology in Albany
- Richard HolubAlbany$6.3M
- Krupa PandeyAlbany$3.8M
- Charles ArgoffAlbany$1.7M
- David HartAlbany$1.7M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.